Invention Grant
- Patent Title: Combination of Bcl-2 inhibitor and MEK inhibitor for the treatment of cancer
-
Application No.: US15767914Application Date: 2016-11-03
-
Publication No.: US10959993B2Publication Date: 2021-03-30
- Inventor: Mark Merchant , Deepak Sampath , Marina Konopleva , Lina Han
- Applicant: Genentech, Inc. , Board of Regents, The University of Texas System
- Applicant Address: US CA South San Francisco; US TX Austin
- Assignee: Genentech, Inc.,Board of Regents, The University of Texas System
- Current Assignee: Genentech, Inc.,Board of Regents, The University of Texas System
- Current Assignee Address: US CA South San Francisco; US TX Austin
- Agency: Armstrong Teasdale LLP
- International Application: PCT/US2016/060271 WO 20161103
- International Announcement: WO2017/079399 WO 20170511
- Main IPC: A61K31/5365
- IPC: A61K31/5365 ; A61K31/497 ; A61K31/4523 ; A61K45/06 ; A61K31/496 ; A61P35/02
Abstract:
The present invention is directed to a combination therapy involving a selective Bcl-2 inhibitor and a MEK inhibitor for the treatment of a patient in need of such a therapy. The patient in need of the combination therapy is suffering from cancer, such as acute myeloid leukemia.
Public/Granted literature
- US20180303815A1 COMBINATION OF BCL-2 INHIBITOR AND MEK INHIBITOR FOR THE TREATMENT OF CANCER Public/Granted day:2018-10-25
Information query
